PDCD1 and melanoma: This is consistent with previous findings that progenitor exhausted TILs can respond to anti-PD-1 therapy, but terminally exhausted TILs cannot; and melanoma patients who have a higher percentage of progenitor exhausted cells experience a longer duration of response to checkpoint-blockade therapy [41].